Annette Matthies, Ph.D.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Annette Matthies, Ph.D.
Elicio Therapeutics, Inc. reported in an 8-K filed October 12, 2023 that Annette Matthies, Ph.D. was terminated as Chief Business Officer, effective October 5, 2023.
“On October 5, 2023, Annette Matthies, Ph.D., Chief Business Officer of Elicio Therapeutics, Inc. (the "Company") was terminated without cause, effective as of the same date (the "Separation Date").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Elicio Therapeutics, Inc. (ELTX)
SEC 8-K
2023-06-01–2023-10-05
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.